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Abstract
Orphan drugs are often approved under exceptional circumstances, requiring submission of additional data on
safety and effectiveness through registries. These registries are mainly focused on one drug only and data is
frequently incomplete. Some registries also address phenotypic heterogeneity and natural history data and
publications on these aspects have contributed to the knowledge and awareness of these rare diseases. However,
for the assessment of long-term outcomes and for cost-effectiveness, the incompleteness and variable quality of
the data raises concerns on the usefulness of these registries. The existing registries for orphan drug treatments for
lysosomal storage disorders (LSD’s) illustrate these limitations. LSD’s are inherited disorders of lysosomal metabolism
with a wide variety in clinical symptoms, ranging from severe life-threatening neurological disease to mild or even
asymptomatic cases. Their prevalence is extremely low and thus data is scarce and scattered all over Europe. In the
past few years, several enzyme replacement therapies and an oral substrate inhibitor have been developed which
provide lifelong treatment of LSD’s. For Fabry disease, two enzymes were authorized at the same time resulting in
two different drug registries being required by the European Medicines Agency (EMA) to monitor effectiveness and
safety. This has lead to patient data being divided between two separate registries which may have contributed to
delays in the assessment of important outcomes. Three treatments (including a recently approved new enzyme)
have now been authorized for Gaucher Disease and two other potential therapies are in the pipeline. Dividing up
the data on Gaucher disease patients in to five separate registries benefits nobody. We argue that disease specific
(rather than drug specific) registries, supervised by independent clinicians are urgently needed for the best long-
term evaluation of treatments of these rare diseases.
Introduction
The European Union enacted the Orphan Drug Regula-
tion in 2000 ( (EC) No 141/2000 and (EC) No 847/2000)
in order to improve the availability of innovative medicines
for diseases affecting less than 5/10 000 people. Incentives
to pharmaceutical companies include 10 years of market
exclusivity, direct access to a Centralized Procedure for
Marketing Authorization, scientific advice and fee reduc-
tions. Some orphan medicinal products (OMP’s), espe-
cially those for extremely rare conditions, are approved by
the European Medicines Agency (EMA) under “excep-
tional circumstances” due to the fact that it is unlikely that
comprehensive data from clinical trials will become
available [1]. Instead, pharmaceutical companies may be
required to collect long-term data in a drug registry as
part of their authorization. It is important to understand
that registries can serve multiple purposes and therefore
need different elements. With the increasing use of regis-
tries, requirements for each specific purpose are now
better defined [2]. For example, registries that serve a pub-
lic health purpose, such as those that are developed for
population surveillance, do not need clinical data beyond
diagnosis or follow-up data. On the other hand, registries
that are being used to assess the effectiveness and safety of
agents after authorization require more stringent elements.
For these regulatory drug registries, completeness of case
ascertainment, high quality clinical data, verification of
data validity and follow-up is mandatory [2]. Existing drug
registries for evaluation of the effectiveness of treatments
for some orphan diseases have certain limitations in this
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respect. This has particularly become clear for the lysoso-
mal storage disorders (LSD’s). The LSD’s comprise a
group of very rare disorders which are all due to a defi-
ciency of a lysosomal enzyme and display a variable range
of phenotypes. Over the last two decades extremely costly
treatments have been developed for these disorders. There
are some differences between the LSD’s and other orphan
diseases for which OMP’s were developed that may have
contributed to the frequent requirement of drug registries
for LSD treatments by the EMA
Differences between OMP’s for lysosomal storage
disorders and other indications
In May 2010, the EMA held a conference to evaluate 10
years of Orphan Regulation in Europe. Over the past dec-
ade, this legislation has resulted in the approval of 62
OMP’s out of > 700 OMP designations [3]. Of these 62
orphan drugs, the majority were for cancer treatments
(35.5%), with the next highest being for metabolic dis-
eases and miscellaneous disorders (both 24.2%), followed
by cardiovascular and respiratory disorders (8.1%),
immunological (4.8%) and musculoskeletal and nervous
system disease (3.2%). Post-authorization requirements
differed: 54% were authorized without specific require-
ments, while 41% of OMP’s were authorized “under
exceptional circumstances” and 5% received “conditional
approval”, the latter meaning that results of additional
studies will be needed for full authorization. Within the
relatively large group of metabolic diseases, the majority
are LSD’s (8 products for 7 diseases, including one pro-
duct for two diseases and in two cases two enzymes for
one disease). These orphan products are mainly enzymes
produced in genetically engineered cell lines, which need
to be administered intravenously. Oral substrate inhibi-
tors have been developed as well, although miglustat
(Zavesca) is the only one that has received approval so
far. An authorization “under exceptional circumstances”
and a requirement to install post-marketing drug regis-
tries are common for OMP’s that are indicated for LSD’s.
With the exception of Myozyme for Pompe’s disease, all
OMP’s for LSD’s have been authorized under exceptional
circumstances. This is most likely explained by the
extreme rarity of LSD’s: the prevalence of the diseases for
which an OMP has been approved is higher than 1 in
10.000 in more than half of the cases, whereas the preva-
lence of LSD’s vary between 1 in 600.000 and 1 in 37.000
[4-7], see table 1. Since the LSD’s for which OMP’s are
currently available, usually have a slow progressive course
and require lifelong treatment, it takes a long time before
additional effectiveness and safety data becomes available.
The European authorities therefore depend heavily on
the outcomes of these registries for final authorization.
The need for a post-marketing surveillance system to
improve our understanding of long term effectiveness
and safety of treatments for LSD’s is not debated and
LSD registries have proven to add meaningful data [8].
However, the EMA requires separate post-marketing
registries for each drug, even when more OMP’s are
available for one rare disease. In addition, the current
drug registries do not sufficiently fulfill the requirements
for a regulatory registry. The following examples will
illustrate the limitations and challenges of the current
drug registries.
Fabry disease
Fabry disease is an X-linked lysosomal storage disorder
resulting from deficient activity of the enzyme alfa-galac-
tosidase A [9]. Storage of globotriaosylceramide in the
vascular wall underlies the pathophysiology [10]. Male
patients typically develop painful acroparesthesia fol-
lowed by proteinuria, renal failure, cardiac hypertrophy
and cerebral white matter lesions. Females are carriers
and may present a wider range of symptoms. For Fabry
disease, two enzymes were granted marketing approval
under exceptional circumstances by the EMA in 2002.
Both enzymes were tested in small placebo-controlled
studies of short duration, that heavily lent on surrogate
end points and limited clinical effectiveness parameters
[11,12]. Following approval, both pharmaceutical compa-
nies, Shire Human Genetic Therapies for Replagal and
Genzyme Corporation for Fabrazyme, were asked to pro-
vide data for annual reassessment of the benefit/risk pro-
file of their product. Both companies set up a drug
registry, (called the Fabry Outcome Survey (FOS) and
Fabry Registry respectively). Although each has a board
of independent advisors, the pharmaceutical company
manages each database. The situation whereby two com-
petitive enzymes were approved at the same time each
being evaluated separately resulted in treatment centers
being generally involved with only one of the products.
In essence, identical datasets were being collected and
separate working groups established to address, for
example, data on females or children, or effects of treat-
ment on the kidney. It needs to be acknowledged that
since these registries did not only address long term
effectiveness and safety outcomes, but also focused on
natural history data and diversity of disease manifesta-
tions, they have added important information. Increased
awareness and a better understanding of the natural
course of the disease, specific involvement such as the
heart, and symptoms in females and pediatric patients,
has been achieved [13-18]. The existence of two regis-
tries, however, has also resulted in publications that were
quite similar [13,14]. Importantly, however, reports from
the registries on the longer term outcomes of ERT, (the
primary motive behind the requirements for these regis-
tries) have been scarce and have only been published
using the FOS registry [19,20]. From these publications it
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is clear that datasets that are complete and accurate
enough for analysis are usually extremely small compared
to the total number of patients in the registry [20]. This
may also be caused by the fact that the quality of the data
is variable due to the lack of standardization of assess-
ments. For example, renal function can be measured in
different ways with different levels of accuracy [21].
Whether the selection of such a small sample results in a
bias is difficult to ascertain, but is certainly a risk. In
addition, comparator data from untreated patients is
usually lacking. The paucity of high quality long term
studies makes it difficult to understand the true health
benefit of enzyme therapy in Fabry disease [22]. This is a
particular challenge since the disease is highly heteroge-
neous. For example, it only gradually became clear that
in patients with advanced disease the process of dete-
rioration could not be stopped [23-25]. Although it is
believed that early therapy could be beneficial, no studies
have convincingly shown that occurrence of organ
damage can be prevented. How the enzymes compare to
each other is another unresolved issue [24]. So far,
physicians and researchers have not sufficiently joined
forces to initiate multi-center studies independent from
industry to address these important longer term out-
comes. The lack of collaboration and the separation of
data in the two drug registries have undoubtedly contrib-
uted to the fact that after almost 10 years experience
with Fabrazyme and Replagal, the most important ques-
tions such as the benefit of early therapy, the comparison
of drugs and the influence of antibodies, remain largely
unanswered resulting in having to conduct further clini-
cal studies.
Gaucher disease
Gaucher disease is the first disorder for which an enzyme
therapy was developed. This disorder results from defi-
cient activity of the lysosomal enzyme glucocerebrosidase
and is clinically characterized by hepatosplenomegaly,
cytopenia with fatigue and bleeding, and devastating
bone complications [26]. Cerezyme (imiglucerase) was
licensed in Europe in 1994, before the European Orphan
Drug legislation was enacted. This treatment has proven
Table 1 Orphan Medicinal Products for lysosomal storage disorders
Lysosomal storage
disorder (ordered by date
of orphan drug
designation of 1st drug)
Range of
birth
prevalence
per 100.000
[ref]*
Estimated
mean
prevalence*
Authorized Orphan drug designation
Fabry disease 2.7 [7] 1 in
37.000**
Replagal Fabrazyme 1-deoxy- galactonojirimycin
hydrochloride
Gaucher disease 1.16-1.75 [4-6] 1 in 70.000 Cerezyme# Zavesca Vpriv Taliglucerase alfa Eliglustat tartrate##
Isofagomine tartrate
MPS IH+IS (Hurler/Scheie) 1.14-1.33 [4-6] 1 in 80.000 Aldurazyme
Glycogen Storage Disease
type II (Pompe’s disease)
0.17-2.0 [4-6] 1 in 90.000 Myozyme Rec. adeno-associated viral
vector containing human
acid alpha-glucosidase-gene
Mucopolysaccharidosis type
VI (Maroteaux-Lamy)
0.15-0.43 [4-6] 1 in 300.000 Naglazyme
Mucopolysaccharidosis type
II (Hunter syndrome)
0.67-1.09 [4-6] 1 in 120.000 Elaprase
Niemann Pick disease
type B
0.10 [6] 1 in
1.000.000
Rec. human acid
sphingomyelinase
Metachromatic
Leukodystrophy
1.09-1.85 [4-6] 1 in 70.000 Autologous CD34+ cells
transfected with lentiviral
vector containing human
arylsulfatase A cDNA
Rec.Human
Arylsulfatase A
Niemann-Pick Disease, type
C
0.35-2.20 [4-6] 1 in 100.000 Zavesca
Mucopolysaccharidosis, type
IIIA (Sanfilippo A syndrome)
0-1.16 [4-6] 1 in 150.000 Recombinant human
heparan-N-sulfatase
Mucopolysaccharidosis, type
IVA (Morquio A Syndrome)
0.22-0.6 [4-6] 1 in 250.000 N-terminal hexaglutamine-
tagged rec. human N-acetyl
galactosamine-6-sulfate
sulfatase
Rec. human N-
acetylgalactosamine-
6-sulfatase
*Birth prevalence values are based upon literature references 4-7, as summarized by Pinto et al [6]. Lowest and highest prevalence values are given (range). The
mean prevalence is estimated from these numbers. ** Recent studies point to an increase in birth prevalence of classical Fabry disease [7]. #Cerezyme was
licensed before 2000, and is officially not an OMP. ## Eliglustat tartrate has and OD designation as (1R,2R)-octanoic acid[2-(2’,3’-dihydro-benzo[1,4] dioxin-6’-yl)-2-
hydroxy- 1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt. Rec = recombinant.
Hollak et al. Orphanet Journal of Rare Diseases 2011, 6:16
http://www.ojrd.com/content/6/1/16
Page 3 of 6
to be extremely beneficial in reversing the major manifes-
tations of Gaucher disease [26]. Following this tremen-
dous success, many questions remained unanswered.
Since the disorder is extremely heterogeneous, ranging
from asymptomatic cases to severe forms in childhood,
debates followed on optimal dosing, costs, timing of
initiation and prevention of long term complications
[27]. The Gaucher Registry was launched in 1991 by
Genzyme to collect data on longer term outcomes as well
as on the natural history of the disease. Following a
Health Technology Assessment conference at the
National Institutes of Health (NIH) in 1995, it was sug-
gested that NIH initiate and foster the establishment of a
cooperative group of investigators in order to create a
patient registry for the analysis of data on natural history
and response to therapy [28]. This initiative was not fol-
lowed through and the Gaucher Registry was further
expanded and now contains information on over 5,500
patients. Some interesting publications have arisen from
its data, including a number of studies on the variability
and rate of improvement of different disease parameters
[29-31]. However, variability of assessments and lack of
completeness limits its use for robust analyses. For exam-
ple, in a dose-efficacy analysis, only a subgroup of 366
patients from the registry were analyzed and although
the study showed that responses were dose dependent,
important outcomes on rates of complication or quality
of life could not be extracted [32]. In a study on cost
effectiveness of ERT, Connock and coworkers concluded
that “Gaucher Registry data, which potentially repre-
sented the richest source of observational data for this
purpose, were inadequate for the task in hand”[33]. They
also expressed concern that the decisions about analyses
of Gaucher Registry data largely depend on people who
have an interest in the product and recommended that
analysis of registry data should be undertaken in such a
way that analytical, reporting and publication biases are
minimised [33].
Although the Gaucher Registry allows the addition of
data on untreated patients as well as on patients treated
with competitive products, fragmentation of data with
new OMP’s entering the market remains a real concern.
A second treatment for Gaucher disease with the oral
substrate inhibitor Zavesca was licensed in 2002 as an
OMP [34]. As part of post-marketing commitments to
the EMA, a safety database was set up but this was not
designed to evaluate efficacy. Apart from a switch study,
no comparative data is available and the registries operate
separately. In the near future, data on effectiveness of
Gaucher treatment will become increasingly difficult to
assess: two new enzymes have recently been developed:
velaglucerase (h-GCB, Shire Human genetic Therapies,
MA, USA), and taliglucerase (pr-GCD, Protalix Biothera-
peutics, Carmiel, Israel). Velaglucerase has recently
received marketing authorization in Europe and the
EMA has again required, post marketing safety data
which will be collected by the company in a drug registry.
If this will also be required for taliglucerase and also for
the new substrate inhibitor eliglustat (Genzyme Corp) in
the course of development, five different drug registries
for a single rare disorder will exist. The rapidly increasing
number of OMP’s for LSD’s illustrates that this will only
lead to further fragmentation of data (table 1).
Summary of limitations of drug-registries
Quality and completeness of the data
Submission of data to drug registries depends on the will-
ingness and cooperation of individual physicians. As a
consequence, the data in these databases may be of vari-
able quality and are usually incomplete. For example, phy-
sicians may not enter data or use different criteria to
define (say) a bone crisis or radiological abnormality in the
skeleton in Gaucher disease. Biomarker analyses are
usually impossible to analyze as the variability in assays
produce insurmountable hurdles. In addition, the datasets
are usually narrowly focused and some important outcome
data may be missed.
Lack of transparency
Firstly, as mentioned, the pharmaceutical companies
manage the registries, with boards consisting of treating
physicians and scientists having a role in formulating
research questions. However, the analyses are performed
by statisticians and epidemiologists employed or commis-
sioned by the pharmaceutical company. The board will
discuss the results of analyses, but will usually not have
access to the source data from the registry. This problem
could be overcome by using an independent group of sta-
tisticians and/or epidemiologists or by granting free
access to the data on request. This requires rules that are
agreed upon by the clinicians, the patient organizations,
the regulatory agencies and the pharmaceutical company.
Second, the yearly reports that are submitted to EMA
are not open to the public. The entire discussion on
safety and effectiveness is between the company and the
EMA. Only when safety issues require the issuing of a
“Direct Healthcare Professional Communication”, will
the community be informed. The recent shortage of
imiglucerase and agalsidase beta and subsequent issues
with enzyme supplies were only disclosed at a late stage.
This was partially to do with the obligations of the com-
pany to inform and receive guidance from EMA first
and led to EMA issuing guidelines to the Gaucher and
Fabry community that were not discussed with the
treating physicians and were also not in line with expert
opinion [35]. Data on the effect of the shortage are diffi-
cult to extract from the drug registries and understand-
ing the clinical effects of switching to alternative
treatments is an even bigger challenge.
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Fragmentation of data
When more than one product for an orphan disease
reaches the market, post-marketing requirements to set
up a drug registry will inevitably result in fragmentation
of data and lack of collaboration between treatment cen-
ters. In addition, studies on cost-effectiveness are carried
out on a national level instead of a European level,
usually initiated as a result of concern over the high price
of the drugs. A huge amount of governmental money is
spent on analyses of national datasets that are too limited
to give meaningful results. If outcomes result in aban-
doning access to some of the drugs from the health care
reimbursement system, this will be on the basis of insuffi-
cient data.
Conclusions
We conclude that collaboration on a European level and
between all stakeholders is needed to improve the evalua-
tion of orphan drugs for LSD’s. To avoid fragmentation
of data, disease registries, rather than drug registries
should be established. Such registries should facilitate not
only the collection of high quality data on safety and
effectiveness for each drug [2], but should also compare
outcomes. More importantly, with a board of indepen-
dent experts in the lead, consisting of physicians, patient
representatives, epidemiologists and statisticians, unifor-
mity of evaluation should be guaranteed. A major chal-
lenge is to enhance the quality and completeness of the
data, which needs systems and resources for data valida-
tion and management. To achieve this, systems should be
developed that support physicians to submit data, in line
with defined requirements [3]. When physicians are not
reporting to the registry, they might consider transferring
their patients to a center of expertise that does. These
registries should be supervised and analyses performed
by an independent body and access to data should be
possible on request. They should be audited at regular
intervals. This approach will save money for both indus-
try and national governments, as instead of supporting
multiple registries, there would be only one. As there is a
mutual interest from companies, physicians and govern-
ments the financial burden should be shared through a
public-private partnership, in the best interest of the
patients and of the community at large.
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